Vaxcyte Inc. PCVX, +59.37% priced its initial public offering late Thursday at $16 a share, the top end of its price range, and upzied the deal to 15.6 million shares from earlier plans to sell just 14 million. The company raised $249.6 million. The shares will start trading on Nasdaq later Friday under the ticker symbol “PCVX.” BofA Securities, Jefferies and Evercore ISI were lead underwriters on the deal with Cantor and Needham acting as co-managers. “We are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide,” says the prospectus. Proceeds of the deal will be used top fund clinical development and for general corporate purposes.